How should multiple myeloma research change in a patient-oriented world? Findings and lessons from the pan-Canadian myeloma priority setting partnership.
Multiple myeloma
Patient and public involvement
Patient engagement
Priority setting
Journal
Research involvement and engagement
ISSN: 2056-7529
Titre abrégé: Res Involv Engagem
Pays: England
ID NLM: 101708164
Informations de publication
Date de publication:
29 Jul 2023
29 Jul 2023
Historique:
received:
14
04
2023
accepted:
20
07
2023
medline:
30
7
2023
pubmed:
30
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Over the last decade there has been considerable research into the treatment, management, and quality of life of people living with multiple myeloma. However, there has been limited investigation into topics deemed important to patients and caregivers within this community. We conducted a James Lind Alliance Priority Setting Partnership to establish the 'Top 10 Priorities for Myeloma Research', informed by patient and public partners. A research team and steering group were established in 2019 to conduct the myeloma priority setting partnership. Steering group members included patients, caregivers, and healthcare providers who advised the research team and oversaw the scope of the project, grounded on their lived experience. Following the James Lind Alliance guidelines for identification and ranking of research questions, we used surveys and a virtual workshop to collect and prioritize questions posed by myeloma patients, caregivers, and healthcare providers across Canada. The Top 10 list of priorities for myeloma research was finalized at the consensus-building workshop and encompassed questions related to diagnosis, treatment, management, and living well with myeloma. A final participant evaluation survey elicited a positive response. The myeloma priority setting partnership identified the research priorities of people living with myeloma, caregivers, and healthcare providers to inform clinical research on this disease going forward. This project underscores the importance of patient and public engagement in the identification of research questions, highlighting the concerns of people affected by myeloma to ultimately improve the lives of people living with this disease. Research on multiple myeloma, a rare blood cancer, rarely focuses on topics that are personally important to people living with myeloma, their caregivers, and their healthcare providers. The purpose of this study was to complete a priority setting partnership, following guidelines from the James Lind Alliance, to identify unanswered research questions from people directly affected by myeloma. The project was guided by a steering group of people living with myeloma, their caregivers, and healthcare providers who informed all stages of this process including two questionnaires to collect and rank questions and a priority setting workshop. The workshop brought together representatives from each group to form the final ‘Top 10 Priorities for Myeloma Research’, which included questions related to diagnosis, treatment, management, and living well with myeloma. This process allowed us to identify the research priorities of the myeloma community and highlighted the importance of including patients and the public as team members in the research process. We encourage other myeloma researchers to do the same to ensure research is meaningful and relevant to the communities who rely on it.
Sections du résumé
BACKGROUND
BACKGROUND
Over the last decade there has been considerable research into the treatment, management, and quality of life of people living with multiple myeloma. However, there has been limited investigation into topics deemed important to patients and caregivers within this community. We conducted a James Lind Alliance Priority Setting Partnership to establish the 'Top 10 Priorities for Myeloma Research', informed by patient and public partners.
METHODS
METHODS
A research team and steering group were established in 2019 to conduct the myeloma priority setting partnership. Steering group members included patients, caregivers, and healthcare providers who advised the research team and oversaw the scope of the project, grounded on their lived experience. Following the James Lind Alliance guidelines for identification and ranking of research questions, we used surveys and a virtual workshop to collect and prioritize questions posed by myeloma patients, caregivers, and healthcare providers across Canada.
RESULTS
RESULTS
The Top 10 list of priorities for myeloma research was finalized at the consensus-building workshop and encompassed questions related to diagnosis, treatment, management, and living well with myeloma. A final participant evaluation survey elicited a positive response.
INTERPRETATION
CONCLUSIONS
The myeloma priority setting partnership identified the research priorities of people living with myeloma, caregivers, and healthcare providers to inform clinical research on this disease going forward. This project underscores the importance of patient and public engagement in the identification of research questions, highlighting the concerns of people affected by myeloma to ultimately improve the lives of people living with this disease.
Research on multiple myeloma, a rare blood cancer, rarely focuses on topics that are personally important to people living with myeloma, their caregivers, and their healthcare providers. The purpose of this study was to complete a priority setting partnership, following guidelines from the James Lind Alliance, to identify unanswered research questions from people directly affected by myeloma. The project was guided by a steering group of people living with myeloma, their caregivers, and healthcare providers who informed all stages of this process including two questionnaires to collect and rank questions and a priority setting workshop. The workshop brought together representatives from each group to form the final ‘Top 10 Priorities for Myeloma Research’, which included questions related to diagnosis, treatment, management, and living well with myeloma. This process allowed us to identify the research priorities of the myeloma community and highlighted the importance of including patients and the public as team members in the research process. We encourage other myeloma researchers to do the same to ensure research is meaningful and relevant to the communities who rely on it.
Autres résumés
Type: plain-language-summary
(eng)
Research on multiple myeloma, a rare blood cancer, rarely focuses on topics that are personally important to people living with myeloma, their caregivers, and their healthcare providers. The purpose of this study was to complete a priority setting partnership, following guidelines from the James Lind Alliance, to identify unanswered research questions from people directly affected by myeloma. The project was guided by a steering group of people living with myeloma, their caregivers, and healthcare providers who informed all stages of this process including two questionnaires to collect and rank questions and a priority setting workshop. The workshop brought together representatives from each group to form the final ‘Top 10 Priorities for Myeloma Research’, which included questions related to diagnosis, treatment, management, and living well with myeloma. This process allowed us to identify the research priorities of the myeloma community and highlighted the importance of including patients and the public as team members in the research process. We encourage other myeloma researchers to do the same to ensure research is meaningful and relevant to the communities who rely on it.
Identifiants
pubmed: 37516883
doi: 10.1186/s40900-023-00476-9
pii: 10.1186/s40900-023-00476-9
pmc: PMC10386308
doi:
Types de publication
Journal Article
Langues
eng
Pagination
60Informations de copyright
© 2023. The Author(s).
Références
Clin Cancer Res. 2016 Nov 15;22(22):5419-5427
pubmed: 28151709
J Cancer Res Clin Oncol. 2023 Apr;149(4):1561-1568
pubmed: 35579718
Res Involv Engagem. 2015 Jun 25;1:2
pubmed: 29062491
BMJ Open. 2019 Aug 5;9(8):e028119
pubmed: 31383701
Clin Cancer Res. 2016 Nov 15;22(22):5428-5433
pubmed: 28151710
Res Involv Engagem. 2020 Nov 19;6(1):68
pubmed: 33292829
Lancet. 2004 Nov 27-Dec 3;364(9449):1923-4
pubmed: 15566996
Br J Haematol. 2022 Mar;196(5):e52-e54
pubmed: 34741302
Res Involv Engagem. 2020 Jul 11;6:41
pubmed: 32670611
J R Soc Med. 2013 Dec;106(12):482-91
pubmed: 23824330
Lancet. 2000 Jun 10;355(9220):2037-40
pubmed: 10885355
Oncologist. 2020 Sep;25(9):e1406-e1413
pubmed: 32335971
Lancet. 2021 Jan 30;397(10272):410-427
pubmed: 33516340
Br J Cancer. 2012 Mar 13;106(6):1021-6
pubmed: 22374464
CMAJ Open. 2022 Mar 29;10(1):E278-E287
pubmed: 35351780
Cancer. 2019 Jul 15;125(14):2435-2444
pubmed: 30951209
Res Involv Engagem. 2023 Mar 8;9(1):7
pubmed: 36890591